Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON9 olaparib with or without cediranib maintenance in relapsed platinum-sensitive ovarian cancer
2017-000161-75Phase 3Unknown
- Sponsor
- University College London
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Olaparib + cediranib maintenance with Olaparib maintenance (2 arms). Primary endpoints: Progression-free survival and Overall survival. Status: unknown.
02
Drugs
olaparibcediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-000161-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000161-75.